Abstract:Background and Objectives Ezetimibe/simvastatin combination tablet has been approved for the treatment of high low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia or mixed hypercholesterolaemia as adjunctive therapy to diet, when diet alone is insufficient in lowering cholesterol. The aims of this study were to assess the pharmacokinetics and safety of an ezetimibe/simvastatin combination tablet after oral single-dose administration in healthy Chinese subjects including sex-related differences in pharmacokinetics. Methods This was an open-label, single-dose study. Twelve healthy subjects (six males and six females) received a single dose of an ezetimibe/simvastatin combination tablet (ezetimibe 10 mg and simvastatin 40 mg). The pharmacokinetic parameters for ezetimibe and simvastatin were assessed by determining total ezetimibe, free ezetimibe, simvastatin and simvastatin acid concentrations using a validated liquid chromatography–tandem mass spectrometry method. Safety was evaluated by monitoring adverse events, laboratory assays, vital signs, physical examinations and 12-lead electrocardiograms. Results The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C max ) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C max (t max ) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t ½ ) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration–time curve from time zero to the time of the last measurable concentration (AUC last ) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively. The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C max 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t max 0.98 ± 0.28 and 3.73 ± 1.68 h, t ½ 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC last 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL. Higher AUC last and AUC from time zero to infinity (AUC ∞ ), and lower apparent total body clearance of drug from plasma after oral administration (CL/F) for total ezetimibe and free ezetimibe were observed in female subjects compared with those in male subjects. There were no differences between the pharmacokinetic parameters of simvastatin and simvastatin acid for female and male subjects in the study. Conclusion Ezetimibe/simvastatin combination tablet has a generally favourable safety and tolerability profile in healthy Chinese subjects. A statistically significant difference with regard to sex in the pharmacokinetics of ezetimibe was observed. Sex had no effect on the pharmacokinetics of simvastatin and simvastatin acid.

The pharmacokinetic characters of simvastatin after co-administration with Shexiang Baoxin Pill in healthy volunteers’ plasma

Study on the Effect of Fenofibrate to Pharmacokinetics of Simvastatin in Healthy Volunteers

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

Simvastatin Pharmacokinetics in Healthy Chinese Subjects and Its Relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 Polymorphisms.

Integrated metabolomics and network pharmacology to reveal the mechanisms of Shexiang Baoxin pill against atherosclerosis

Integrated Network Pharmacology and Fecal Metabolomic Analysis of the Combinational Mechanisms of Shexiang Baoxin Pill Against Atherosclerosis.

Pharmacokinetic Study of Five Ginsenosides Using a Sensitive and Rapid Liquid Chromatography–tandem Mass Spectrometry Method Following Single and Multiple Oral Administration of Shexiang Baoxin Pills to Rats

Effect of Constituents Combination on Pharmacokinetics of Shuxiong Tablet

Pharmacokinetics and safety of ezetimibe/simvastatin combination tablet: an open-label, single-dose study in healthy Chinese subjects.

A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases

Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet

Comparative pharmacokinetics of 11 major bioactive components between two dosage forms of Qixue Shuangbu Prescription in rats by ultra‐high‐performance liquid chromatography‐tandem mass spectrometry

Simultaneous Determination of Ginsenosides and Bufadienolides in Rat Plasma after the Oral Administration of Shexiang Baoxin Pill for Pharmacokinetic Study by Liquid Chromatography Tandem Mass Spectrometry Following Solid-Phase Extraction.

Metabolomic strategy for studying the intervention and the synergistic effects of the shexiang baoxin pill for treating myocardial infarction in rats.

Simultaneous Determination of Four Volatile Compounds in Rat Plasma after Oral Administration of Shexiang Baoxin Pill (SBP) by HS-SPDE-GC-MS/MS and Its Application to Pharmacokinetic Studies.

Analysis of the Constituents in Rat Plasma after Oral Administration of Shexiang Baoxin Pill by Hplc-Esi-Ms/Ms

Effect of Shexiang Baoxin Pill Combined with Atorvastatin on Acute Myocardial Infarction and Its Effect on Vascular Endothelial Function and Cardiac Function

The Effect of Herbal Medicine Baicalin on Pharmacokinetics of Rosuvastatin, Substrate of Organic Anion‐transporting Polypeptide 1B1

Simultaneous Quantification of 11 Active Constituents in Shexiang Baoxin Pill by Ultraperformance Convergence Chromatography Combined with Tandem Mass Spectrometry

Effects of Shuxuetong Injection on Activities of Six Isoforms of Cytochrome P450 in Rats

The effectiveness of borneol on pharmacokinetics changes of four ginsenosides in Shexiang Baoxin Pill in vivo.